{"organizations": [], "uuid": "4b84e57c46bacfe7f68e7226f135084daec324cb", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-palatin-technologies-initiates-sub/brief-palatin-technologies-initiates-subject-dosing-in-first-in-human-clinical-study-of-pl-8177-idUSFWN1PV0VL", "country": "US", "domain_rank": 408, "title": "BRIEF-Palatin Technologies Initiates Subject Dosing In First-In-Human Clinical Study Of Pl-8177", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-05T14:39:00.000+02:00", "replies_count": 0, "uuid": "4b84e57c46bacfe7f68e7226f135084daec324cb"}, "author": "", "url": "https://www.reuters.com/article/brief-palatin-technologies-initiates-sub/brief-palatin-technologies-initiates-subject-dosing-in-first-in-human-clinical-study-of-pl-8177-idUSFWN1PV0VL", "ord_in_thread": 0, "title": "BRIEF-Palatin Technologies Initiates Subject Dosing In First-In-Human Clinical Study Of Pl-8177", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "palatin technologies inc", "sentiment": "none"}, {"name": "palatin", "sentiment": "none"}, {"name": "palatin technologies inc", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 42 PM / in 8 minutes BRIEF-Palatin Technologies Initiates Subject Dosing In First-In-Human Clinical Study Of Pl-8177 Reuters Staff 1 Min Read \nFeb 5 (Reuters) - Palatin Technologies Inc: \n* PALATIN TECHNOLOGIES, INC. INITIATES SUBJECT DOSING IN FIRST-IN-HUMAN CLINICAL STUDY OF PL-8177, AN INVESTIGATIONAL MELANOCORTIN RECEPTOR 1 AGONIST \n* PALATIN TECHNOLOGIES INC - TOP LINE DATA FROM STUDY OF PL-8177 IS CURRENTLY EXPECTED IN Q3 OF 2018 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-02-05T14:39:00.000+02:00", "crawled": "2018-02-05T14:57:54.072+02:00", "highlightTitle": ""}